Ocugen Just Overcame a Serious Hurdle InvestorPlace 3/4/2021 Alex Sirois © Source: Shutterstock A needle rests on a reflective table next two clear glass vials of a clear liquid.
Investors will pile into
Ocugen (NASDAQ:
OCGN) stock based on its recent price movement. The shares have rallied because yesterday Ocugen received very promising news regarding the Phase 3 trial results of Covaxin, a vaccine for the novel coronavirus. But Ocugen still has a significant battle in front of it. © Provided by InvestorPlace A needle rests on a reflective table next two clear glass vials of a clear liquid.
The company has gone from working to develop gene therapies for eye diseases to becoming involved in a potential coronavirus vaccine. Specifically, Ocugen signed a deal with Indian company
Ocugen Establishes Vaccine Scientific Advisory Board
mychesco.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mychesco.com Daily Mail and Mail on Sunday newspapers.
Ocugen Establishes Vaccine Scientific Advisory Board – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ocugen Establishes Vaccine Scientific Advisory Board
OcugenDecember 24, 2020 GMT
MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies, today announced the appointment of a vaccine scientific advisory board comprised of leading academic and industry experts in the vaccine field to evaluate the clinical and regulatory path to approval in the US market of Bharat Biotech’s COVAXIN™, a whole-virion inactivated COVID-19 vaccine candidate to be co-developed by Ocugen and Bharat Biotech for the US market.